COMP <GO>
EXEL vs ABBV // NET PROFIT MARGIN
Exelixis Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: EXEL 11
— ABBV 4
▲ NET PROFIT MARGIN LEADER: EXEL
LAST: $69.39 (+4.82%) • MKT CAP: $16.40B
net-margins
33.70%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
net-margins
6.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EXEL VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EXEL | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 70.20% | +25.80 | EXEL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 35.10% | 29.00% | +6.10 | EXEL | /roic <GO> |
| EV/EBITDA & P/E Valuation | 18.4x | 33.3x | -14.90 | EXEL | /valuation <GO> |
| Free Cash Flow Yield | 5.34% | 3.47% | +1.87 | EXEL | /fcf-yield <GO> |
| Operating Margin | 37.60% | 24.60% | +13.00 | EXEL | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 33.70% | 6.90% | +26.80 | EXEL | /net-margins <GO> |
| Revenue Growth (YoY) | 7.00% | 8.60% | -1.60 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 16.64 | 5.33 | +11.31 | EXEL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | EXEL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 7.40% | -0.60 | EXEL | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 81.7 | 72.8 | +8.87 | EXEL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.96 | 1.15 | -0.19 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 19.5x | 113.1x | -93.60 | EXEL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $16.40B | $513.86B | -$497.46B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EXEL REV | ABBV REV | EXEL GROSS % | ABBV GROSS % | EXEL FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.32B | $61.16B | 96.4% | 70.2% | $875.8M | $17.82B |
| FY 2024 | $2.17B | $56.33B | 96.5% | 70.0% | $671.5M | $17.83B |
| FY 2023 | $1.83B | $54.32B | 44.0% | 44.0% | $251.0M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EXEL // BETA 0.96
ABBV // BETA 1.15